Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey

V. C. Pandey, S. K. Puri, Sanjeev Sahni, P. Srivastava, G. P. Dutta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A potential anti-relapse antimalarial compound CDRI 80/53 [N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] at 7.5 mg/kg body weight and primaquine at 6.0 mg/kg body weight did not cause any significant change in the status of hepatic microsomal mixed function oxidase system of rhesus monkeys, when given orally for 7 days. Further, the extension of the treatment at the same dossier up to 21 days resulted in impairment of the different indices of the MFO system. The compound CDRI 80/53 inhibited cytochrome P-450, aminopyrine-N-demethylase, aniline and benzo(a)pyrene hydroxylases, cytochrome b5 and haem levels by 17, 11, 58, 0, 36 and 35% whereas the inhibition caused by primaquine was 34, 40, 72, 54, 39 and 38% respectively, establishing that the cytochrome P-450 dependent mono-oxygenase system of monkey liver was comparatively less suppressed by compound CDRI 80/53. The cessation of the compound/drug treatment resulted in almost complete reversal of all the MFO activities to normal in a period of about 6 weeks.

Original languageEnglish (US)
Pages (from-to)701-707
Number of pages7
JournalPharmacological Research
Volume22
Issue number6
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Primaquine
Antimalarials
Mixed Function Oxygenases
Macaca mulatta
Recurrence
Cytochrome P-450 Enzyme System
Liver
Benzopyrene Hydroxylase
Aminopyrine N-Demethylase
Body Weight
Cytochromes b5
Oxygenases
Heme
Haplorhini
Pharmaceutical Preparations
bulaquine

Keywords

  • anti-relapse antimalarial
  • CDRI 80/53
  • MFO system
  • primaquine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey. / Pandey, V. C.; Puri, S. K.; Sahni, Sanjeev; Srivastava, P.; Dutta, G. P.

In: Pharmacological Research, Vol. 22, No. 6, 1990, p. 701-707.

Research output: Contribution to journalArticle

@article{c2f1c3527db84e4d86354a8696bc2305,
title = "Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey",
abstract = "A potential anti-relapse antimalarial compound CDRI 80/53 [N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] at 7.5 mg/kg body weight and primaquine at 6.0 mg/kg body weight did not cause any significant change in the status of hepatic microsomal mixed function oxidase system of rhesus monkeys, when given orally for 7 days. Further, the extension of the treatment at the same dossier up to 21 days resulted in impairment of the different indices of the MFO system. The compound CDRI 80/53 inhibited cytochrome P-450, aminopyrine-N-demethylase, aniline and benzo(a)pyrene hydroxylases, cytochrome b5 and haem levels by 17, 11, 58, 0, 36 and 35{\%} whereas the inhibition caused by primaquine was 34, 40, 72, 54, 39 and 38{\%} respectively, establishing that the cytochrome P-450 dependent mono-oxygenase system of monkey liver was comparatively less suppressed by compound CDRI 80/53. The cessation of the compound/drug treatment resulted in almost complete reversal of all the MFO activities to normal in a period of about 6 weeks.",
keywords = "anti-relapse antimalarial, CDRI 80/53, MFO system, primaquine",
author = "Pandey, {V. C.} and Puri, {S. K.} and Sanjeev Sahni and P. Srivastava and Dutta, {G. P.}",
year = "1990",
doi = "10.1016/S1043-6618(05)80096-9",
language = "English (US)",
volume = "22",
pages = "701--707",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey

AU - Pandey, V. C.

AU - Puri, S. K.

AU - Sahni, Sanjeev

AU - Srivastava, P.

AU - Dutta, G. P.

PY - 1990

Y1 - 1990

N2 - A potential anti-relapse antimalarial compound CDRI 80/53 [N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] at 7.5 mg/kg body weight and primaquine at 6.0 mg/kg body weight did not cause any significant change in the status of hepatic microsomal mixed function oxidase system of rhesus monkeys, when given orally for 7 days. Further, the extension of the treatment at the same dossier up to 21 days resulted in impairment of the different indices of the MFO system. The compound CDRI 80/53 inhibited cytochrome P-450, aminopyrine-N-demethylase, aniline and benzo(a)pyrene hydroxylases, cytochrome b5 and haem levels by 17, 11, 58, 0, 36 and 35% whereas the inhibition caused by primaquine was 34, 40, 72, 54, 39 and 38% respectively, establishing that the cytochrome P-450 dependent mono-oxygenase system of monkey liver was comparatively less suppressed by compound CDRI 80/53. The cessation of the compound/drug treatment resulted in almost complete reversal of all the MFO activities to normal in a period of about 6 weeks.

AB - A potential anti-relapse antimalarial compound CDRI 80/53 [N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] at 7.5 mg/kg body weight and primaquine at 6.0 mg/kg body weight did not cause any significant change in the status of hepatic microsomal mixed function oxidase system of rhesus monkeys, when given orally for 7 days. Further, the extension of the treatment at the same dossier up to 21 days resulted in impairment of the different indices of the MFO system. The compound CDRI 80/53 inhibited cytochrome P-450, aminopyrine-N-demethylase, aniline and benzo(a)pyrene hydroxylases, cytochrome b5 and haem levels by 17, 11, 58, 0, 36 and 35% whereas the inhibition caused by primaquine was 34, 40, 72, 54, 39 and 38% respectively, establishing that the cytochrome P-450 dependent mono-oxygenase system of monkey liver was comparatively less suppressed by compound CDRI 80/53. The cessation of the compound/drug treatment resulted in almost complete reversal of all the MFO activities to normal in a period of about 6 weeks.

KW - anti-relapse antimalarial

KW - CDRI 80/53

KW - MFO system

KW - primaquine

UR - http://www.scopus.com/inward/record.url?scp=0025666365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025666365&partnerID=8YFLogxK

U2 - 10.1016/S1043-6618(05)80096-9

DO - 10.1016/S1043-6618(05)80096-9

M3 - Article

VL - 22

SP - 701

EP - 707

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 6

ER -